Identification of genetic lesions associated with diffuse large-cell lymphoma

R. Dalla-Favera, B. Hilda Ye, F. Lo Coco, G. Gaidano, F. Lista, D. M. Knowles, D. C. Louie, K. Offit, R. S K Chaganti

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: The pathogenesis of several subtypes of non-Hodgkin's lymphoma (NHL) is associated with specific genetic lesions involving oncogenes and tumor-suppressor genes. These lesions inlude c-myc translocation and p53 inactivation in small noncleaved-cell lymphoma, and bcl-2 and bcl-1 translocation in follicular (FL) and mantle-zone lymphoma, respectively. Relatively little is known, however, about the pathogenesis of diffuse lymphoma with a large-cell component (DLLC; including large-, mixed-cell, and immunoblastic), the most relevant NHL type in terms of morbidity and mortality. Since DLLC can occur 'de novo' or via histologic transformation of follicular lymphoma, it is critical to identify lesions associated with both pathogenctic pathways. Design: The present work is aimed at (i) identifying the role of cytogenetic and molecular lesions involving oncogenes or tumor-suppressor genes in the transformation of FL into DLLC in a series of 5 patients for whom sequential biopsies were available pre- and post-transformation and (ii) identifying novel proto-oncogenes involved in DLLC pathogenesis by molecular analysis of chromosomal translocations affecting hand 3q27, which are common in DLLC. Results: Mutations of the p53 gene were detected in 4 of 5 cases displaying histologic transformation from follicular to diffuse-type NHL. A novel proto-oncogene, bcl-6, coding for a zinc-finger transcription factor, was cloned from 3q27 breakpoints and shown to be structurally altered in 33% (13/39) of DLLC samples studied, but not in other types of lymphoid malignancies. Conclusions: These results indicate that inactivation of the p53 tumor-suppressor gene may complement bcl-2 activation and be involved in the transformation of FL into DLLC. Activation of the bcl-6 oncogene may represent one of the steps in the pathogenesis of 'de novo' DLLC. Both lesions should prove useful as diagnostic and prognostic markers in the clinical management of these tumors.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalAnnals of Oncology
Volume5
Issue numberSUPPL. 1
StatePublished - 1994
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Tumor Suppressor Genes
Oncogenes
Proto-Oncogenes
Complement C2
Mantle-Cell Lymphoma
Genetic Translocation
Follicular Lymphoma
Zinc Fingers
p53 Genes
Cellular Structures
Cytogenetics
Neoplasms
Transcription Factors
Hand
Biomarkers
Morbidity
Biopsy
Mutation

Keywords

  • bcl-6
  • histologic transformation
  • lymphoma
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dalla-Favera, R., Ye, B. H., Lo Coco, F., Gaidano, G., Lista, F., Knowles, D. M., ... Chaganti, R. S. K. (1994). Identification of genetic lesions associated with diffuse large-cell lymphoma. Annals of Oncology, 5(SUPPL. 1), 55-60.

Identification of genetic lesions associated with diffuse large-cell lymphoma. / Dalla-Favera, R.; Ye, B. Hilda; Lo Coco, F.; Gaidano, G.; Lista, F.; Knowles, D. M.; Louie, D. C.; Offit, K.; Chaganti, R. S K.

In: Annals of Oncology, Vol. 5, No. SUPPL. 1, 1994, p. 55-60.

Research output: Contribution to journalArticle

Dalla-Favera, R, Ye, BH, Lo Coco, F, Gaidano, G, Lista, F, Knowles, DM, Louie, DC, Offit, K & Chaganti, RSK 1994, 'Identification of genetic lesions associated with diffuse large-cell lymphoma', Annals of Oncology, vol. 5, no. SUPPL. 1, pp. 55-60.
Dalla-Favera R, Ye BH, Lo Coco F, Gaidano G, Lista F, Knowles DM et al. Identification of genetic lesions associated with diffuse large-cell lymphoma. Annals of Oncology. 1994;5(SUPPL. 1):55-60.
Dalla-Favera, R. ; Ye, B. Hilda ; Lo Coco, F. ; Gaidano, G. ; Lista, F. ; Knowles, D. M. ; Louie, D. C. ; Offit, K. ; Chaganti, R. S K. / Identification of genetic lesions associated with diffuse large-cell lymphoma. In: Annals of Oncology. 1994 ; Vol. 5, No. SUPPL. 1. pp. 55-60.
@article{78d3cb68fb5a4c2f8be13e0522ff6838,
title = "Identification of genetic lesions associated with diffuse large-cell lymphoma",
abstract = "Background: The pathogenesis of several subtypes of non-Hodgkin's lymphoma (NHL) is associated with specific genetic lesions involving oncogenes and tumor-suppressor genes. These lesions inlude c-myc translocation and p53 inactivation in small noncleaved-cell lymphoma, and bcl-2 and bcl-1 translocation in follicular (FL) and mantle-zone lymphoma, respectively. Relatively little is known, however, about the pathogenesis of diffuse lymphoma with a large-cell component (DLLC; including large-, mixed-cell, and immunoblastic), the most relevant NHL type in terms of morbidity and mortality. Since DLLC can occur 'de novo' or via histologic transformation of follicular lymphoma, it is critical to identify lesions associated with both pathogenctic pathways. Design: The present work is aimed at (i) identifying the role of cytogenetic and molecular lesions involving oncogenes or tumor-suppressor genes in the transformation of FL into DLLC in a series of 5 patients for whom sequential biopsies were available pre- and post-transformation and (ii) identifying novel proto-oncogenes involved in DLLC pathogenesis by molecular analysis of chromosomal translocations affecting hand 3q27, which are common in DLLC. Results: Mutations of the p53 gene were detected in 4 of 5 cases displaying histologic transformation from follicular to diffuse-type NHL. A novel proto-oncogene, bcl-6, coding for a zinc-finger transcription factor, was cloned from 3q27 breakpoints and shown to be structurally altered in 33{\%} (13/39) of DLLC samples studied, but not in other types of lymphoid malignancies. Conclusions: These results indicate that inactivation of the p53 tumor-suppressor gene may complement bcl-2 activation and be involved in the transformation of FL into DLLC. Activation of the bcl-6 oncogene may represent one of the steps in the pathogenesis of 'de novo' DLLC. Both lesions should prove useful as diagnostic and prognostic markers in the clinical management of these tumors.",
keywords = "bcl-6, histologic transformation, lymphoma, p53",
author = "R. Dalla-Favera and Ye, {B. Hilda} and {Lo Coco}, F. and G. Gaidano and F. Lista and Knowles, {D. M.} and Louie, {D. C.} and K. Offit and Chaganti, {R. S K}",
year = "1994",
language = "English (US)",
volume = "5",
pages = "55--60",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Identification of genetic lesions associated with diffuse large-cell lymphoma

AU - Dalla-Favera, R.

AU - Ye, B. Hilda

AU - Lo Coco, F.

AU - Gaidano, G.

AU - Lista, F.

AU - Knowles, D. M.

AU - Louie, D. C.

AU - Offit, K.

AU - Chaganti, R. S K

PY - 1994

Y1 - 1994

N2 - Background: The pathogenesis of several subtypes of non-Hodgkin's lymphoma (NHL) is associated with specific genetic lesions involving oncogenes and tumor-suppressor genes. These lesions inlude c-myc translocation and p53 inactivation in small noncleaved-cell lymphoma, and bcl-2 and bcl-1 translocation in follicular (FL) and mantle-zone lymphoma, respectively. Relatively little is known, however, about the pathogenesis of diffuse lymphoma with a large-cell component (DLLC; including large-, mixed-cell, and immunoblastic), the most relevant NHL type in terms of morbidity and mortality. Since DLLC can occur 'de novo' or via histologic transformation of follicular lymphoma, it is critical to identify lesions associated with both pathogenctic pathways. Design: The present work is aimed at (i) identifying the role of cytogenetic and molecular lesions involving oncogenes or tumor-suppressor genes in the transformation of FL into DLLC in a series of 5 patients for whom sequential biopsies were available pre- and post-transformation and (ii) identifying novel proto-oncogenes involved in DLLC pathogenesis by molecular analysis of chromosomal translocations affecting hand 3q27, which are common in DLLC. Results: Mutations of the p53 gene were detected in 4 of 5 cases displaying histologic transformation from follicular to diffuse-type NHL. A novel proto-oncogene, bcl-6, coding for a zinc-finger transcription factor, was cloned from 3q27 breakpoints and shown to be structurally altered in 33% (13/39) of DLLC samples studied, but not in other types of lymphoid malignancies. Conclusions: These results indicate that inactivation of the p53 tumor-suppressor gene may complement bcl-2 activation and be involved in the transformation of FL into DLLC. Activation of the bcl-6 oncogene may represent one of the steps in the pathogenesis of 'de novo' DLLC. Both lesions should prove useful as diagnostic and prognostic markers in the clinical management of these tumors.

AB - Background: The pathogenesis of several subtypes of non-Hodgkin's lymphoma (NHL) is associated with specific genetic lesions involving oncogenes and tumor-suppressor genes. These lesions inlude c-myc translocation and p53 inactivation in small noncleaved-cell lymphoma, and bcl-2 and bcl-1 translocation in follicular (FL) and mantle-zone lymphoma, respectively. Relatively little is known, however, about the pathogenesis of diffuse lymphoma with a large-cell component (DLLC; including large-, mixed-cell, and immunoblastic), the most relevant NHL type in terms of morbidity and mortality. Since DLLC can occur 'de novo' or via histologic transformation of follicular lymphoma, it is critical to identify lesions associated with both pathogenctic pathways. Design: The present work is aimed at (i) identifying the role of cytogenetic and molecular lesions involving oncogenes or tumor-suppressor genes in the transformation of FL into DLLC in a series of 5 patients for whom sequential biopsies were available pre- and post-transformation and (ii) identifying novel proto-oncogenes involved in DLLC pathogenesis by molecular analysis of chromosomal translocations affecting hand 3q27, which are common in DLLC. Results: Mutations of the p53 gene were detected in 4 of 5 cases displaying histologic transformation from follicular to diffuse-type NHL. A novel proto-oncogene, bcl-6, coding for a zinc-finger transcription factor, was cloned from 3q27 breakpoints and shown to be structurally altered in 33% (13/39) of DLLC samples studied, but not in other types of lymphoid malignancies. Conclusions: These results indicate that inactivation of the p53 tumor-suppressor gene may complement bcl-2 activation and be involved in the transformation of FL into DLLC. Activation of the bcl-6 oncogene may represent one of the steps in the pathogenesis of 'de novo' DLLC. Both lesions should prove useful as diagnostic and prognostic markers in the clinical management of these tumors.

KW - bcl-6

KW - histologic transformation

KW - lymphoma

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0028029110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028029110&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 55

EP - 60

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -